A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole

Aliment Pharmacol Ther. 1994;8 Suppl 1:53-7. doi: 10.1111/j.1365-2036.1994.tb00253.x.

Abstract

The efficacy and safety of pantoprazole in the treatment of duodenal and gastric ulcers has been compared with that of the first proton pump inhibitor omeprazole in two (previously reported) clinical studies. Pantoprazole (40 mg/day) administered orally was an effective and well-tolerated treatment for both indications. Pantoprazole was as effective as omeprazole (20 mg/day) and had a similar safety profile. For gastric ulcers, the healing rate with pantoprazole was superior to that with omeprazole at 4 weeks.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adolescent
  • Adult
  • Aged
  • Benzimidazoles / adverse effects
  • Benzimidazoles / therapeutic use*
  • Double-Blind Method
  • Duodenal Ulcer / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Omeprazole / adverse effects
  • Omeprazole / therapeutic use*
  • Pantoprazole
  • Proton Pump Inhibitors*
  • Randomized Controlled Trials as Topic
  • Stomach Ulcer / drug therapy*
  • Sulfoxides / adverse effects
  • Sulfoxides / therapeutic use*

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Proton Pump Inhibitors
  • Sulfoxides
  • Pantoprazole
  • Omeprazole